Want to see TRAX full AI Analyst Report?

First Tracks Biotherapeutics Inc (TRAX) Price & Analysis

44 Followers

TRAX Stock Chart & Stats

$41.86

Market closed

$41.86

Day’s Range― - ―

52-Week Range$14.72 - $49.91

Previous CloseN/A

VolumeN/A

Average Volume (3M)665.30K

Market Cap

$1.29B

Enterprise Value$548.38

Total Cash (Recent Filing)$168.02M

Total Debt (Recent Filing)$4.33M

Price to Earnings (P/E)―

Beta1.53

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding35,730,843

10 Day Avg. Volume869,780

30 Day Avg. Volume665,305

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)2.30

Price to Sales (P/S)0.00

P/FCF Ratio-4.62

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$68.70

Price Target Upside64.12% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative LeverageVery low leverage gives the company more financial flexibility than a highly indebted biotechnology issuer, because limited debt obligations reduce fixed cash demands. This can preserve strategic options and provide greater capacity to manage losses or pursue funding alternatives over the coming quarters.

Positive Equity BaseThe company still has a substantial positive equity base, which provides some balance-sheet support while its development activities remain unprofitable. Although the decline is a concern, existing equity may help sustain operations and preserve flexibility during the next several quarters.

Improved Free Cash Flow TrendAn improvement in the reported year-over-year free-cash-flow growth measure offers a limited constructive signal about cash-flow direction. It does not offset the large absolute deficit, but continued improvement could reduce funding pressure if sustained across future reporting periods.

Bears Say

No Commercial RevenueThe absence of revenue across three reporting years indicates that the company has not yet established a commercial funding engine. Without product sales, operations remain dependent on external capital or existing resources, making progress toward sustainable profitability uncertain over the next several quarters.

Worsening Net LossesLarge and worsening net losses show that operating spending continues to materially exceed any economic return from the business. Persistent losses can consume equity, increase reliance on financing, and make a transition to self-funded growth more difficult over the medium term.

Heavy Cash BurnEscalating operating cash burn means the reported losses are translating into substantial real cash outflows rather than being primarily non-cash charges. Continued negative free cash flow implies ongoing funding needs and raises the risk of future capital pressure or dilution.

First Tracks Biotherapeutics Inc News

First Tracks Biotherapeutics initiated with a Buy at Canaccord

Canaccord initiated coverage of First Tracks Biotherapeutics (TRAX) with a Buy rating and $50 price target The firm’s...

18h ago

TRAX

First Tracks Biotherapeutics initiated with a Buy at Canaccord

Canaccord initiated coverage of First Tracks Biotherapeutics (TRAX) with a Buy rating and $50 price target Published first...

20h ago

TRAX

First Tracks Biotherapeutics initiated with an Outperform at Evercore ISI

Evercore ISI initiated coverage of First Tracks Biotherapeutics (TRAX) with an Outperform rating and $65 price target The...

13d ago

TRAX

First Tracks Biotherapeutics initiated with a Buy at Guggenheim

Guggenheim initiated coverage of First Tracks Biotherapeutics (TRAX) with a Buy rating and $100 price target The firm...

15d ago

TRAX

Analyst Reiterates Buy on TRAX as IL-15/CD122 Data De-Risk Celiac Program; $57 Price Target Maintained

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on First Tracks Biotherapeutics Inc today and set a...

28d ago

TRAX

First Tracks Biotherapeutics reports Q2 EPS (95c), consensus (80c)

“First Tracks continues to execute against a broad development strategy for our potentially best-in-class CD122 antagonist, ANB033, and...

1M ago

TRAX

First Tracks Biotherapeutics price target raised to $65 from $48 at Barclays

Barclays raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $65 from $48 and keeps an...

1M ago

TRAX

First Tracks price target raised to $57 from $44 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $57 from $44 and keeps...

1M ago

TRAX

First Tracks Biotherapeutics price target raised to $95 from $54 at Piper Sandler

Piper Sandler raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $95 from $54 based on...

1M ago

TRAX

First Tracks Biotherapeutics management to meet with Piper Sandler

Meeting to be held on August 17-18 hosted by Piper Sandler. Published first on TheFly – the ultimate...

2M ago

TRAX

First Tracks Biotherapeutics price target raised to $65 from $45 at UBS

UBS raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $65 from $45 and keeps a...

2M ago

TRAX

First Tracks Biotherapeutics: Buy Rating Reaffirmed with Unchanged $44 Price Target on ANB033 CD122-Targeting Upside and Acquisition Potential

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on First Tracks Biotherapeutics Inc, retaining the price...

2M ago

TRAX

Buy Rating on First Tracks (TRAX) Driven by Strengthening IL-15/CD122 Pathway Validation and Upcoming ANB033 Clinical Catalysts in Celiac Disease and Vitiligo

In a report released yesterday, Emily Bodnar from H.C. Wainwright maintained a Buy rating on First Tracks Biotherapeutics...

3M ago

TRAX

Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on First Tracks Biotherapeutics Inc, retaining the price...

5M ago

TRAX

TRAX FAQ

What was First Tracks Biotherapeutics Inc’s price range in the past 12 months?

First Tracks Biotherapeutics Inc lowest stock price was $14.72 and its highest was $49.91 in the past 12 months.

What is First Tracks Biotherapeutics Inc’s market cap?

First Tracks Biotherapeutics Inc’s market cap is $1.29B.

When is First Tracks Biotherapeutics Inc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were First Tracks Biotherapeutics Inc’s earnings last quarter?

Currently, no data Available

Is First Tracks Biotherapeutics Inc overvalued?

According to Wall Street analysts First Tracks Biotherapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does First Tracks Biotherapeutics Inc pay dividends?

First Tracks Biotherapeutics Inc does not currently pay dividends.

What is First Tracks Biotherapeutics Inc’s EPS estimate?

First Tracks Biotherapeutics Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does First Tracks Biotherapeutics Inc have?

First Tracks Biotherapeutics Inc has 35,730,843 shares outstanding.

What happened to First Tracks Biotherapeutics Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of First Tracks Biotherapeutics Inc?

Currently, no hedge funds are holding shares in TRAX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

First Tracks Biotherapeutics Inc Stock Smart Score

Neutral

Company Description

First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

First Tracks Biotherapeutics Inc (TRAX) Earnings & Revenues

Historic Earnings Reports

TRAX Stock 12 Month Forecast

Average Price Target

$68.70

▲(64.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","38":"$38","59":"$59","80":"$80","101":"$101"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$68.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,38,59,80,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.17,45.69538461538462,50.220769230769235,54.746153846153845,59.27153846153846,63.79692307692308,68.32230769230769,72.84769230769231,77.37307692307692,81.89846153846153,86.42384615384616,90.94923076923077,95.47461538461539,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.17,43.28769230769231,45.40538461538462,47.52307692307693,49.64076923076924,51.758461538461546,53.87615384615385,55.99384615384616,58.111538461538466,60.229230769230774,62.34692307692308,64.46461538461539,66.5823076923077,{"y":68.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.17,41.84923076923077,42.52846153846154,43.20769230769231,43.886923076923075,44.566153846153846,45.245384615384616,45.924615384615386,46.603846153846156,47.283076923076926,47.96230769230769,48.64153846153846,49.32076923076923,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.38,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.09,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.59,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.17,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >